DBV Technologies (DBVT) Total Current Liabilities (2014 - 2026)
DBV Technologies (DBVT) reported Total Current Liabilities of $51.8 million for Q1 2026, up 28.27% year-over-year from $40.4 million in Q1 2025, and down 10.69% on a QoQ basis from $58.0 million in Q4 2025.
DBV Technologies (DBVT) has 13 years of Total Current Liabilities data on file, last reported at $51.8 million in Q1 2026.
- Quarterly Total Current Liabilities rose 28.27% year-over-year to $51.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $51.8 million (up 28.27% YoY) and the FY2025 annual result came in at $58.0 million, up 86.28% from the prior year.
- Total Current Liabilities eased to $51.8 million in Q1 2026 per DBVT's latest filing, from $58.0 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $58.0 million in Q4 2025 and bottomed at $26.0 million in Q1 2022.
- The 5-year median for Total Current Liabilities is $31.4 million (2023), against an average of $36.1 million.
- The widest annual swing landed in 2022, when Total Current Liabilities sank 32.96%; it then soared 86.28% in 2025.
- Tracing DBVT's Total Current Liabilities over 5 years: stood at $29.5 million in 2022, then rose by 26.48% to $37.3 million in 2023, then retreated by 16.61% to $31.1 million in 2024, then surged by 86.28% to $58.0 million in 2025, then dropped by 10.69% to $51.8 million in 2026.
- Per Business Quant, the three latest DBVT Total Current Liabilities figures stand at $51.8 million (Q1 2026), $58.0 million (Q4 2025), and $49.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.11 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.35 Bn |
| 10 | DBV Technologies | 8.00 Bn | 7.77 Bn | -3.90 Mn | 51.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 51.80 Mn |
| Dec 31, 2025 | 58.00 Mn |
| Sep 30, 2025 | 49.49 Mn |
| Jun 30, 2025 | 49.43 Mn |
| Mar 31, 2025 | 40.38 Mn |
| Dec 31, 2024 | 31.14 Mn |
| Sep 30, 2024 | 30.91 Mn |
| Jun 30, 2024 | 27.38 Mn |
| Mar 31, 2024 | 26.48 Mn |
| Dec 31, 2023 | 37.34 Mn |
| Sep 30, 2023 | 31.44 Mn |
| Jun 30, 2023 | 33.37 Mn |
| Mar 31, 2023 | 32.78 Mn |
| Dec 31, 2022 | 29.52 Mn |
| Sep 30, 2022 | 28.39 Mn |
| Jun 30, 2022 | 30.43 Mn |
| Mar 31, 2022 | 26.03 Mn |
| Dec 31, 2021 | 31.40 Mn |
| Sep 30, 2021 | 33.81 Mn |
| Jun 30, 2021 | 38.70 Mn |
| Mar 31, 2021 | 38.83 Mn |
| Dec 31, 2020 | 52.71 Mn |
| Jun 30, 2020 | 61.22 Mn |
| Dec 31, 2019 | 53.21 Mn |
| Sep 30, 2019 | 49.37 Mn |
| Jun 30, 2019 | 51.46 Mn |
| Dec 31, 2018 | 49.70 Mn |
| Jun 30, 2018 | 41.68 Mn |
| Dec 31, 2017 | 42.31 Mn |
| Jun 30, 2017 | 35.74 Mn |
| Dec 31, 2016 | 31.31 Mn |
| Jun 30, 2016 | 27.71 Mn |
| Dec 31, 2015 | 17.56 Mn |
| Jun 30, 2015 | 8.74 Mn |
| Dec 31, 2014 | 6.94 Mn |